Company Description
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States.
The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations.
It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases; and Modified HSV-1, which is in the discovery phase, for the treatment of modified colorectal cancer.
The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease.
It also has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders.
The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 14, 2023 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Vininder Singh |
Contact Details
Address: 325 Ellington Boulevard, Unit 317 Gaithersburg, Maryland 20878 United States | |
| Phone | 240 658 6710 |
| Website | bullfrogai.com |
Stock Details
| Ticker Symbol | BFRG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.50 |
| CIK Code | 0001829247 |
| ISIN Number | US12021E1091 |
| Employer ID | 84-4786155 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Vininder Singh | Founder, Chairman and Chief Executive Officer |
| J. T. Koffenberger | Chief Information Officer |
| Dr. Cetin Savkli Ph.D. | Chief AI Advisor and Member of Advisory Board |
| Dr. David P. Recker FACP, FACR, M.D. | Chief Medical Officer |
| Dr. Praveen Kudithipudi M.B.A., M.D. | Chief Business Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 3, 2025 | 144 | Filing |
| Mar 14, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Jan 14, 2025 | SCHEDULE 13G | Filing |
| Jan 6, 2025 | 144 | Filing |
| Dec 27, 2024 | 8-K | Current Report |
| Dec 17, 2024 | 8-K | Current Report |
| Dec 12, 2024 | 8-K | Current Report |
| Nov 29, 2024 | EFFECT | Notice of Effectiveness |
| Nov 25, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |